Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
EBV-Specific Anti-PD1 TCR-T Cells by TCR Cure Biopharma Technology for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
EBV-Specific Anti-PD1 TCR-T Cells is under clinical development by TCR Cure Biopharma Technology and currently in Phase II for Recurrent...